People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Verix Health, Inc. | — | Biotechnology | Seed | $1.5M | $66.6M | 2019 |
| EpiVario Inc. | — | Pharmaceuticals | Pre-Seed | $1.1M | $749K | 2018 |
Michael Dishowitz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Dishowitz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Duke Rohlen | 1 | 10 |
| Aftab Kherani | 1 | 9 |
| Doug Koo | 1 | 8 |
| Tony Natale | 1 | 5 |
| Thomas Kim | 1 | 4 |
| Yi-Yen Chen | 1 | 2 |
| Sasha Schrode | 1 | 2 |
| Eric Schultenover | 1 | 1 |
| Philipp Mews | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.